PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 7(4): 253-254 1987
© 1987 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agroyannis, B.
Right arrow Articles by Sarris, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Agroyannis, B.
Right arrow Articles by Sarris, E.

REVIEWS AND ORIGINAL ARTICLES

FERROXIDASE I AND IIIN CAPD PATIENTS

Basil Agroyannis, Hippocrates Yatzidis, Matrona Frangos-Plemenos, Dimitrios Koutsicos, Antony Katirtzoglou and Evangelos Sarris

From the Nephrological Center of Athens University, Aretaieon Univ. Hospital, 11528 Athens, Greece.

In 32 patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and in 56 healthy subjects, ferroxidase I (ceruloplasmin) and ferroxidase II activity were estimated in serum; in 12 of the 32, it was also measured in peritoneal fluid. Serum ferroxidase I was normal, while ferroxidase II was significantly increased. Peritoneal fluid contains appreciable amounts of ferroxidase I, but no ferroxidase II. The serum ferroxidase profile of patients on CAPD differs from that of hemodialysis (HD) patients; in the latter, both ferroxidases are significantly increased. This difference could be accounted by the loss offerroxidase I in the peritoneal fluid.

KEY WORDS: Serum ferroxidase; ferrox-idase loss in peritoneal fluid.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 1987 by Multimed Inc.